Boxel Bio Files PCT Application for Monobody-Based 'CAR-T' Therapy

[Asia Economy Reporter Lee Gwan-joo] Bacsell Bio announced on the 27th that it has completed the international patent (PCT) application for its next-generation chimeric antigen receptor (CAR)-T cell therapy based on the 'Monobody' platform under development.

The Monobody developed by Bacsell Bio is one-third the size of the scFv (single chain fragment variable) commonly used in existing CAR-T therapies, theoretically allowing the simultaneous expression of three receptors. The company explained that this could be a significant advantage in developing CAR-T cell therapies targeting solid tumors, which account for 90% of all cancers.

CAR-T therapy is a next-generation anticancer immunotherapy that involves genetically modifying a patient's immune cells and re-administering them. It treats cancer by activating the patient's immune system through binding a chimeric antigen receptor (CAR), which can track specific antigens on cancer cells, to T cells, a type of immune cell.

A representative from Bacsell Bio stated, “Following the domestic patent application, the international patent application (PCT application) marks a step forward as a leader in CAR-T therapies targeting solid tumors. We will continue to demonstrate advanced results through excellent technological development worldwide.”